The vasodilator drug, papaverine hydrochloride (sustalned-release form) was used in a double-hlind crossover study of 30 geriatric patients with symptoms of chronic hrain syndrome secondary to cerehral arteriosclerosis. At a dosage level of 300 mg twice daily in sustained-release form, papaverine hydrochloride was more effective than placeho in relieving 13 of the 15 target symptoms characterizing the syndrome. Side effects were numerous hut mild, and did not interrupt the study. Drowsiness, constipation and vertigo accounted for 80 per cent of the side effects noted with the active drug, whereas 81.5 per cent of the side effects noted with placeho were nausea, vertigo, headache and flatulence. The drug had no significant effect on the weight of the patient.Papaverine hydrochloride proved to he a valuahle adjunct in the suhjective relief of symptoms of chronic hrain syndrome secondary to cerehral arteriosclerosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.